Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione
1994
Erratum on Plasma and Urinary Oestrogens in Breast Cancer Patients
Sample size: 9
publication
Author Information
Author(s): Johannessen et al.
Conclusion
The erratum corrects the figures and tables related to plasma and urinary oestrogens in breast cancer patients treated with 4-hydroxyandrostenedione.
Supporting Evidence
- Mean values of urinary metabolites showed significant suppression during treatment.
- Total oestrogens decreased from 28.24 pmol/l to 8.47 pmol/l.
Takeaway
This study looked at how a treatment affects hormone levels in breast cancer patients, and the erratum corrects some earlier mistakes in the data.
Methodology
Patients were treated with 250 mg of 4-hydroxyandrostenedione intramuscularly every two weeks.
Participant Demographics
8 postmenopausal women and 1 man.
Statistical Information
P-Value
<0.005
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website